Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, GN, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Xing, G, Chao, M, Ramsingh, G, Renard, C, Lal, I, Zeidner, JF, Sallman, DA

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results by Daver, NG, Vyas, P, Kambhampati, S, Al Malki, MM, Larson, RA, Asch, AS, Mannis, G, Chai-Ho, W, Tanaka, TN, Bradley, TJ, Jeyakumar, D, Wang, ES, Sweet, K, Kantarjian, HM, Garcia-Manero, G, Komrokji, R, Xing, G, Ramsingh, G, Renard, C, Zeidner, JF, Sallman, DA

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial by de Botton, S, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Ommen, H, Semochkin, S, Kim, H-J, Larson, RA, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, MB, Doronin, V, Döhner, H, Fathi, AT, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, DiNardo, CD

International Consensus Classification of myeloid neoplasms and acute leukemia: Integrating morphological, clinical, and genomic data. by Arber, DA, Orazi, A, Hasserjian, RP, Borowitz, MJ, Calvo, KR, Kvasnicka, HM, Wang, SA, Bagg, A, Barbui, T, Branford, S, Bueso-Ramos, CE, Cortes, J, Dal Cin, P, DiNardo, CD, Dombret, H, Duncavage, EJ, Ebert, BL, Estey, E, Facchetti, F, Foucar, K, Gangat, N, Gianelli, U, Godley, LA, Goekbuget, N, Gotlib, JR, Hellström-Lindberg, E, Hobbs, G, Hoffman, R, Jabbour, EJ, Kiladjian, J-J, Larson, RA, Le Beau, MM, Loh, ML, Löwenberg, B, Macintyre, EA, Malcovati, L, Mullighan, CG, Niemeyer, CM, Odenike, O, Ogawa, S, Orfao, A, Papaemmanuil, E, Passamonti, F, Porkka, K, Pui, C-H, Radich, JP, Reiter, A, Rozman, M, Rudelius, M, Savona, MR, Vyas, P